Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ...
bdtonline.com
news
2022-10-20 12:04:20

ERAS-007, a potential best-in-class ERK1/2 inhibitor, is being evaluated in combination with palbociclib in patients with KRAS- and NRAS-mutant colorectal cancer and KRAS-mutant pancreatic cancerErasca previously signed CTCSAs with Pfizer and Lilly to evaluate ERAS-007 in combination with encorafenib and cetuximab SAN DIEGO, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced a clinical trial collaboration and supply agreement (CTCSA) with Pfizer Inc.
